23 protocols found



Protocol No. Title Status
UW18115 Phase I Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW18059 A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Open
UW17136 A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma Open
UW17114 A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Open
UW17098 Phase 1 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy Open
UW17053 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
UW17003 Comprehensive stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer (NSCLC) combined with durvalumab and tremelimumab dual immune checkpoint inhibition Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW16063 Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect Open
UW16061 A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) Open
UW16034 Safety of TAS-102 in Combination with Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors Open
UW16009 Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 Open
UW15103 Real-Time MRI-Guided Stereotactic Body Radiation Therapy and Microwave Ablation for Non-Operable Renal Cell Carcinoma Open
UW15063 Pembrolizumab in combination with stereotactic body radiotherapy for liver metastatic colorectal cancer Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW14090 A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Dervived From Three Breast Cancer Antigens (IGFBP-2, HER2, IGF-IR) in Patients With Breast Cancer Open
UW14070 Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma Open
UW14002 A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 Open
RO12210 A phase Ia-Ib dose-escalation study evaluating safety and efficacy of neoadjuvant stereotactic body radiotherapy (SBRT) with concomitant capecitabine-based chemotherapy (ChT) for resectable pancreatic adenocarcinoma Open
NCI9950 A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) Open
NCI9924 A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open